On ECHEMI
Home > Drugs > Isosorbide Mononitrate Injection

Isosorbide Mononitrate Injection

Function and Efficacy

Isosorbide mononitrate (ISMN) is the main biologically active metabolite of isosorbide dinitrate. Like other organic nitrates, its main pharmacological action is to relax vascular smooth muscle. ISMN releases nitric oxide (NO), which is the same as endothelial relaxing factor, activating guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby relaxing vascular smooth muscle, dilating peripheral arteries and veins, and having a stronger dilating effect on veins. Venous dilation causes blood to remain in the periphery, reducing the amount of blood returning to the heart, and reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arterial dilation reduces peripheral vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Coronary artery dilation increases coronary perfusion. The overall effect is to reduce myocardial oxygen consumption, increase oxygen supply, and relieve angina pectoris. No carcinogenic and mutagenic phenomena were observed in animal experiments.

Ingredients

Isosorbide mononitrate

Name Description Content CAS NO. Manufacturer
Isosorbide 5-mononitrateIngredients

Relaxes vascular smooth muscle, reduces myocardial oxygen consumption, increases oxygen supply, and relieves angina. It activates guanylate cyclase by releasing nitric oxide (NO), increases cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby relaxing vascular smooth muscle, dilating peripheral arteries and veins, reducing preload and afterload, and increasing coronary artery perfusion.

More
16051-77-7 22

Appearance

This product is a colorless clear liquid.

Indication

It is suitable for the treatment of angina pectoris and can be used in combination with digitalis and (or) diuretics to treat chronic heart failure.

Usage and Dosage

The effective dose is generally 2-7 mg per hour, adjusted according to the patient's response. The initial administration rate is 60 μg/min, and the general rate is 60-120 μg/min, once a day, and a course of treatment is 10 days.

Adverse Reactions

Nitrate-induced vasodilatory headaches may occur in the early stages of medication, but usually disappear after a few days of continuous use. Facial flushing, dizziness, orthostatic hypotension, and reflex tachycardia may also occur. Occasionally, blood pressure may drop significantly, bradycardia, aggravated angina pectoris, and syncope may occur.

Precautions

Acute circulatory failure (shock, circulatory collapse); severe hypotension (systolic blood pressure 90 mmHg); acute myocardial infarction with low filling pressures (unless under continuous hemodynamic monitoring); hypertrophic obstructive cardiomyopathy; constrictive pericarditis or cardiac tamponade; severe anemia; glaucoma; increased intracranial pressure; allergy to nitro compounds

Drug Interactions

Combination with other vasodilators, calcium antagonists, beta-receptor blockers, antihypertensive drugs, tricyclic antidepressants and alcohol can enhance the blood pressure lowering effect of this class of drugs.

Storage

Sealed, stored in a cool place (no higher than 20℃)

Packaging Specification

5ml:20mg

Manufacturer

YANGTZE River Pharmaceutical Group Nanjing Pharmaceutical. Co., Ltd.

  • Founded in:

    2001-01-16
  • Address:

    No. 9 Xianlin Avenue, Qixia District, Nanjing
  • Tax NO.:

    91320192726063334T
  • Registered Funds:

    50 million yuan
  • Website:

  • Email:

Other Drugs of YANGTZE River Pharmaceutical Group Nanjing Pharmaceutical. Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.